Literature DB >> 25872341

Leiomyosarcoma: a rare malignant transformation of a uterine leiomyoma.

G Di Luigi, A D'Alfonso, F Patacchiola, L Di Stefano, P Palermo, G Carta.   

Abstract

The malignant transformation of a uterine leiomyoma is still debated and, if it occurs, it is very rare. The case of a patient affected by one small leiomyoma is described. Diagnosis was made postoperatively on histopathological examination. The case reported here is meant to underline the need to keep all uterine myomas in check since the transition into leiomyosarcomas (LMSs) may occur with an evolution over a time period which has not been established so far. Specific receptors for luteinizing hormone/human chorionic gonadotropin (LH/hCG) have also been identified in the myometrium of several animal species, including humans. Conventional LMSs express estrogen receptors (ER), progesterone receptors (PR), and androgen receptors (AR) in 30-40% of cases. In comparison with other more common uterine malignancies, uterine LMSs bear some resemblance to type 2 endometrial carcinomas and high-grade serous carcinomas of ovary/fallopian tube origin, based on their genetic instability, frequent p53 abnormalities, aggressive behavior, and resistance to chemotherapy. It could be useful to understand with further researches if hormonal stimulation could be a contributing factor of uterine leiomyoma transformation into LMS. Until today the oncogenic mechanisms underlying the development of uterine LMSs remain elusive.

Entities:  

Mesh:

Year:  2015        PMID: 25872341

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  5 in total

1.  Circulating Sex Hormones and Risk of Uterine Fibroids: Study of Women's Health Across the Nation (SWAN).

Authors:  Jason Y Y Wong; Ellen B Gold; Wesley O Johnson; Jennifer S Lee
Journal:  J Clin Endocrinol Metab       Date:  2015-12-15       Impact factor: 5.958

2.  Surgical Treatment of "Large Uterine Masses" in Pregnancy: A Single-Center Experience.

Authors:  Anna Franca Cavaliere; Annalisa Vidiri; Salvatore Gueli Alletti; Anna Fagotti; Maria Concetta La Milia; Silvia Perossini; Stefano Restaino; Giuseppe Vizzielli; Antonio Lanzone; Giovanni Scambia
Journal:  Int J Environ Res Public Health       Date:  2021-11-19       Impact factor: 3.390

3.  Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.

Authors:  My Linh Thibodeau; Caralyn Reisle; Eric Zhao; Lee Ann Martin; Yazeed Alwelaie; Karen L Mungall; Carolyn Ch'ng; Ruth Thomas; Tony Ng; Stephen Yip; Howard J Lim; Sophie Sun; Sean S Young; Aly Karsan; Yongjun Zhao; Andrew J Mungall; Richard A Moore; Daniel J Renouf; Karen Gelmon; Yussanne P Ma; Malcolm Hayes; Janessa Laskin; Marco A Marra; Kasmintan A Schrader; Steven J M Jones
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-09-01

4.  Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations.

Authors:  Eucharist H S Kun; Yvonne T M Tsang; Sophia Lin; Sophia Pan; Tejas Medapalli; Anais Malpica; JoAnne S Richards; David M Gershenson; Kwong-Kwok Wong
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

5.  A Fast-growing Benign Metastasizing Leiomyoma Mimicking Malignancy.

Authors:  Noboru Hamada; Mitsunori Ishiga; Yasuhiro Ooue; Goro Kimura; Yasushi Tanimoto
Journal:  Intern Med       Date:  2021-07-17       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.